ArticleScience advances2020
A facile technology for the high-throughput sequencing of the paired VH:VL and TCRβ:TCRα repertoires.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The Role of the T Cell Receptor Sequence in Shaping T Cell Functional Fate.Immunological reviews · 2026Review
- Germline-aware deep learning models and benchmarks for predicting antibody VH-VL pairing.mAbs · 2025Article
- A sticky situation - simple method for rapid poissonian encapsulation of highly aggregation-prone microbeads in polydisperse emulsions.Frontiers in bioengineering and biotechnology · 2025Article
- Multiplexed Antibody Sequencing and Profiling of the Human Hemagglutinin-specific Memory B Cell Response following Influenza Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Decoding the mosaic of inflammatory bowel disease: Illuminating insights with single-cell RNA technology.Computational and structural biotechnology journal · 2024Review
- Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.Frontiers in immunology · 2024Review
- Cell activation-based screening of natively paired human T cell receptor repertoires.Scientific reports · 2023Article
- Single-Cell Analysis in Immuno-Oncology.International journal of molecular sciences · 2023Review
- RNA cytometry of single-cells using semi-permeable microcapsules.Nucleic acids research · 2023Article
- One-Pot Droplet RT-OE-PCR for the Generation of Natively Paired Antibody Immune Libraries.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Antibodies to combat viral infections: development strategies and progress.Nature reviews. Drug discovery · 2022Review
- Reconstruction of full antibody sequences in NGS datasets and accurate VComputational and structural biotechnology journal · 2022Article
- High-throughput and single-cell T cell receptor sequencing technologies.Nature methods · 2021Review
- Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.Nature reviews. Clinical oncology · 2021Review
- Dual UMIs and Dual Barcodes With Minimal PCR Amplification Removes Artifacts and Acquires Accurate Antibody Repertoire.Frontiers in immunology · 2021Article
- Beyond bulk single-chain sequencing: Getting at the whole receptor.Current opinion in systems biology · 2020Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Natively paired sequencing (NPS) of B cell receptors [variable heavy (VH) and light (VL)] and T cell receptors (TCRb and TCRa) is essential for the understanding of adaptive immunity in health and disease. Despite many recent technical advances, determining the VH:VL or TCRb:a repertoire with high accuracy and throughput remains challenging. We discovered that the recently engineered xenopolymerase, RTX, is exceptionally resistant to cell lysate inhibition in single-cell emulsion droplets. We capitalized on the characteristics of this enzyme to develop a simple, rapid, and inexpensive in-droplet overlap extension reverse transcription polymerase chain reaction method for NPS not requiring microfluidics or other specialized equipment. Using this technique, we obtained high yields (5000 to >20,000 per sample) of paired VH:VL or TCRb:a clonotypes at low cost. As a demonstration, we performed NPS on peripheral blood plasmablasts and T follicular helper cells following seasonal influenza vaccination and discovered high-affinity influenza-specific antibodies and TCRb:a.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.